Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | VP, Finance and Treasurer | September 27, 2018 | September 28, 2018 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CFO & Treasurer | September 04, 2024 | September 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 27, 2018 · Filed September 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock Option 2015 (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.95 · Expires 2025-12-18 | Direct | 5,400 |
Reported balance
After 2018-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-27 · Grant · Acquired 1,800 · Balance 5,400 F1: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. |
| Performance Stock Option 2016 (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.22 · Expires 2026-12-20 | Direct | 2,775 |
Reported balance
After 2018-09-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-09-27 · Grant · Acquired 1,387 · Balance 2,775 F2: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares.
F2: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares.
Karyopharm Therapeutics Inc.
Report date September 04, 2024 · Filed September 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 391,054 |
Reported balance
After 2024-09-04 transaction · row 1
1 source rowRow 1 · 2024-09-04 · Sale · Disposed 7,050 · Balance 391,054 F1: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2013 (right to buy) · Derivative | 1,667 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · derivative · entry 16 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires 2023-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 600 | $135.00 | $81,000.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 14 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. F7 · price: Sale prices ranged from $134.94 to $135.10 Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 400 | $133.83 | $53,532.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 13 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. F6 · price: Sale prices ranged from $133.78 to $134.11. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,591 | $132.98 | $211,571.18 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 12 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. F5 · price: Sale prices ranged from $132.75 to $133.71. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 12,405 | $132.18 | $1,639,692.90 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 11 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. F4 · price: Sale prices ranged from $131.75 to $132.71. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 16,500 | $131.20 | $2,164,800.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 10 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,996 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. F3 · price: Sale prices ranged from $130.74 to $131.73. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,249 | $130.42 | $684,574.58 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 9 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,496 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. F2 · price: Sale prices ranged from $129.74 to $130.72. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,439 | $63.00 | $216,657.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 8 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 6,187 | $96.45 | $596,736.15 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 7 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $97.72 | $977,200.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 6 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,750 | $96.45 | $265,237.50 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 5 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,750 | $96.45 | $265,237.50 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 4 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,600 | $88.95 | $320,220.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 3 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,667 | $63.00 | $105,021.00 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 2 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 22:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,388 | $42.22 | $58,601.36 |
DisclosureSEC source: 0001325812-18-000004 · edgardoc.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 22:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Exercise / conversionRestricted Stock Unit · Derivative | 8,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000002 · primary_doc.xml · derivative · entry 4 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on December 30, 2017. F3 · derivative.expiration_date: The restricted stock units vest in full on December 30, 2017. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 22:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Tax withholdingCommon Stock | 3,538 | $127.05 | $449,502.90 |
DisclosureSEC source: 0001325812-18-000002 · primary_doc.xml · nonDerivative · entry 2 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,964 Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 22:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALKS · Entity 3132 | Exercise / conversionCommon Stock | 8,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000002 · primary_doc.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 1,388 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-17-000040 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388 Underlying: Common Stock · 1,388 shares Expires 2026-12-20 F1 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 1,800 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000066 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 22, 2017 Filed Feb 9, 2018 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 1,950 | $115.47 | $225,166.50 |
DisclosureSEC source: 0001553878-18-000001 · primary_doc.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account Disclosed balance after: 226 F1 · ownership.nature: The reporting person has diversified his retirement plan by selling shares of ALNY common stock in his 401(k) plan received from the ALNY 401(k) matching contribution program. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2013 (right to buy) · Derivative | 1,667 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000052 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2023-12-17 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective September 20, 2017, the compensation committee of the company determined the second performance criteria had been met and the option will vest as to one-third of the shares. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2014 (right to buy) · Derivative | 2,750 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000045 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 2,750 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-17-000013 · primary_doc.xml · derivative · entry 6 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,625 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001553878-17-000013 · primary_doc.xml · derivative · entry 5 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2021-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9,375 | $70.00 | $656,250.00 |
DisclosureSEC source: 0001553878-17-000013 · primary_doc.xml · nonDerivative · entry 3 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016. Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,750 | $7.10 | $26,625.00 |
DisclosureSEC source: 0001553878-17-000013 · primary_doc.xml · nonDerivative · entry 2 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016. Read SEC document |
| May 16, 2017 Filed May 17, 2017 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,625 | $18.66 | $104,962.50 |
DisclosureSEC source: 0001553878-17-000013 · primary_doc.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 22:33 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 8,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001325812-17-000002 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,502 Underlying: Common Stock · 8,502 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on December 30, 2017. F2 · derivative.expiration_date: The restricted stock units vest in full on December 30, 2017. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,550 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-16-000111 · edgardoc.xml · derivative · entry 1 Mason Michael · CIK 0001514291 · VP, Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2026-12-20 F1 · shares: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 5,550 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.